- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01913418
Clinical Efficacy and Serum Proteomic Profiling of Suan-Zao-Ren Tang for Sleep Disturbance During Methadone Maintenance
Clinical Efficacy and Serum Proteomic Profiling of Traditional Chinese Medicine, Suan-Zao-Ren Tang, for Sleep Disturbance During Methadone Maintenance: Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Heroin dependence is one of the major health issues worldwide. Methadone Maintenance Therapy (MMT) is an effective treatment for opioid dependence, but more than three quarters of persons receiving MMT report sleep complaints. Traditional Chinese Medicine (TCM) is one of the most common complementary therapies offered to insomnia patients in Taiwan. Investigators designed a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of TCM in methadone-maintained persons with sleep disturbance.
Methods/design:
In this study, inclusion criteria are persons receiving MMT for at least one month, more than 20 years old, complain insomnia with a Pittsburgh Sleep Quality Index (PSQI) of six or higher. Exclusion criteria include being pregnancy, had serious physical or mental illness, current use (last 30 days) of TCM, had received any antidepressant or neuroleptic medication and inability to read and fill out the forms for the study. The patients were separated into an intervention group (Suan-Zao-Ren Tang, SZRT) and a placebo group for four weeks using a randomized, double-blind procedure. Outcome measures will be assessed at baseline, 4 weeks and 8 weeks after receiving medication. PSQI was used to assess sleep quality over the past 30 days, anxiety and depression levels measured by the Beck Anxiety Inventory (BAI) and Beck Depression Inventory II (BDI-II) were also conducted, heroin craving degree was evaluated by the change of the visual analog scale (VAS). Serum proteins will be detected using a proteomics method based on two-dimensional gel electrophoresis, and the specificity of proteins will confirmed by western blotting. T-test and chi-square tests are used for statistical analysis.
Discussion:
SZRT is a combination of Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao). It was the most commonly prescribed Chinese herbal formula used for the treatment of insomnia. In the classical literature and previous studies, SZRT was said to calm the nerves and nourish the blood to eventually bring on a tranquillizing sensation and improved the quality of sleep without generating significant side effects. In order to evaluate the efficacy of SZRT for sleep disturbance during methadone maintenance, investigators designed a randomized, double-blind, placebo-controlled trial and perform the proteomic-system biology analysis to find the biomarker associated with sleep condition.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Taoyuan, Taiwan, 325
- Department of psychiatry, Armed Forces Tao-Yuan General Hospital, No.168 Zhong-Xing Road, Taoyuan, Taiwan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged over 20 years
- patients fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for opiate dependence
- patients had been receiving MMT for more than one month
- patients have sleep disturbance complains and with Pittsburgh sleep quality index (PSQI) of greater than six
- Must be able to signed informed consent
Exclusion Criteria:
- had received any antidepressant or neuroleptic medication
- had received any TCM treatment during the previous 30 days
- had any serious physical or mental illness
- had a significant risk of suicide
- pregnancy
- inability to read and fill out the forms for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Suan-Zao-Ren Tang
The SZRT formula used in this study is manufactured as a herbal extract powder from the good manufacturing procedures (GMP) of the certified company Kaiser Pharmaceutical Co., Ltd.
(Taiwan).
Granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
|
SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
|
Placebo Comparator: Suan-Zao-Ren Tang placebo
The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
|
The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
sleep quality
Time Frame: The patients will complete the questionnaire at baseline (first visit), four weeks later (second visit), and eight weeks later (third visit).
|
The primary outcome measure under study is the sleep quality.
Sleep quality will be assessed using the Taiwanese version of the PSQI, which has demonstrated reliability and validity.
It evaluates sleep disturbances in 7subscales: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication and daytime dysfunction.
Each subscale is rated on a 4-point scale (0 to 3, with 3 indicating a more profound effect), which is summed together to yield a global score (0to21).
|
The patients will complete the questionnaire at baseline (first visit), four weeks later (second visit), and eight weeks later (third visit).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
severity of heroin craving
Time Frame: The patients will complete the questionnaire at baseline (first visit), four weeks later (second visit), and eight weeks later (third visit).
|
The severity of heroin craving was assessed using a 100 millimeters visual analog scale (VAS).
|
The patients will complete the questionnaire at baseline (first visit), four weeks later (second visit), and eight weeks later (third visit).
|
Beck Anxiety inventory (BAI)
Time Frame: The patients will complete the questionnaire at baseline (first visit), four weeks later (second visit), and eight weeks later (third visit).
|
This measure lists 21 symptoms of anxiety such as feeling hot, scared or nervous.
Participants will be instructed to rate how much each of these symptoms bothered them in the past week.
Each item can be rated on a 4 point Likert scale, ranging from 0 (Not at all) to 3 (Severely) yielding a maximum total score of 63 points.
|
The patients will complete the questionnaire at baseline (first visit), four weeks later (second visit), and eight weeks later (third visit).
|
Beck Depression Inventory (BDI-II, second edition)
Time Frame: The patients will complete the questionnaire at baseline (first visit), four weeks later (second visit), and eight weeks later (third visit).
|
Depression symptoms will be measured with the BDI-II.
This measure consists of 13 items to evaluate depression, and each item is rated from 0 to 3 according to the degree by which it reflects a patient's state during the previous week.
The BDI has a high reliability, and concurrent validity.
|
The patients will complete the questionnaire at baseline (first visit), four weeks later (second visit), and eight weeks later (third visit).
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NSC 102-2320-B-039-024-
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opiate Dependence
-
Assistance Publique - Hôpitaux de ParisCompletedOpioid-related Disorders | Opiate Dependence | Opiate Addiction | Opiate AbuseFrance
-
Merck Sharp & Dohme LLCCompletedOpiate Dependence | Substance Dependence | Drug Dependence
-
Beth Israel Medical CenterAstraZenecaTerminatedGeneralized Anxiety Disorder | Comorbid Opiate Dependence in Remission | Status Post Methadone-Maintenance TreatmentUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)Completed
-
Imperial College LondonRecruitingAddiction OpiateUnited Kingdom
-
University of CincinnatiNational Institute on Drug Abuse (NIDA); MaryhavenUnknownHeroin Dependence | Opiate Dependence | Substance DependenceUnited States
-
Indivior Inc.CompletedDrug Abuse | Opiate Dependence | Opiate-related Disorders
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedHeroin Dependence | Opiate DependenceUnited States
-
National Institute on Drug Abuse (NIDA)New York MDRUCompletedSubstance-Related Disorders | Heroin DependenceUnited States
-
Indivior Inc.CompletedOpiate Dependence | Drug Dependence
Clinical Trials on Suan-Zao-Ren Tang
-
Central South UniversityThe Third Hospital of Inner Mongolia Autonomous RegionCompletedChronic Insomnia DisorderChina
-
Chung Shan Medical UniversityCompleted
-
Taipei City HospitalNational Taiwan University HospitalUnknownMenopausal WomenTaiwan